Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia.
CONCLUSION: PAE reduced LUTS symptoms in most patients without severe complications. The treatment did not exclude additional surgical treatment when needed. PMID: 30450921 [PubMed - as supplied by publisher]
To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia (BPH) continuously receiving oral anticoagulants or antiplatelet drugs.
ConclusionsThe therapeutic effects of SVCP on treating UTIs might result from the up-regulation of innate immunity in the kidney. SVCP can be used as an alternative therapeutic agent for UTIs.Graphical abstract
Conclusions: In conclusion, UBASH3B may be a novel potential prognostic biomarker and is associated with tumor-infiltrating immune cells in tumor microenvironment, suggesting UBASH3B as a potential target for future treatment of PCa.
CONCLUSION: Our results did not show adequate evidence for any significant association of MLH1 and MSH3 polymorphisms and prostate cancer. PMID: 31953835 [PubMed - as supplied by publisher]
This study aims to compare the efficacy and safety of holmium laser technologies (HoL-Ts) and photoselective greenlight vaporization (PVP) for the treatment of benign prostatic hyperplasia (BPH), and to perform a meta-analysis according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses guidelines on PubMed, EMBASE, ClinicalTrial.gov, and the Cochrane Central Register of Controlled Trials up to August 2019. Functional outcomes, perioperative parameters, and complications were included and analyzed. Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) was used to perform all analyses. A total of six...
Conclusion: By our findings, we conclude that BPH is associated with anatomic variations in posterior urethra such as lengthening of the length of the posterior urethra and increased posterior urethral elevation, which is measured by an increase in posterior urethral angle (PUA). Whereas post-TURP, there is a shortening of posterior urethra, decrease in PUA, decrease in prostatic volume, postvoid residual urine volume, and improvement in uroflowmetric parameters.
This study aimed to evaluate the efficacy of electroacupuncture (EA) on Ciliao (BL 32) and Zhongliao (BL 33) acupoints at different depths for the treatment of benign prostatic hyperplasia (BPH) through a single-blind randomized controlled trial. All 120 patients diagnosed with BPH were randomly allocated to an experimental group (deep insertion group, DI group, n = 60) and control group (shallow insertion group, SI group, n = 60) 3 times a week for 4 weeks. The observed results included the International Prostate Symptom Score (IPSS), Quality of Life score (QOL), maximum urine flow rate (Qmax),...
ConclusionsAlthough with an evidence level IV (based on expert opinion) the use of Pygeum africanum seems to be an option in the urological therapeutic arsenal.ResumenContextoEl Pygeum africanum sigue siendo utilizado por parte de los urólogos para el tratamiento de los síntomas urinarios del Tracto Urinario Inferior secundarios a Hiperplasia Benigna de Próstata.Adquisición de la evidenciaSe ha realizado una revisión no exhaustiva sobre el Pygeum africanum, sus mecanismos de acción, tanto “in vitro “como “in vivo”, de los ensayos clínicos y en la pr&a...
A new review provides insight into the epidemiology of benign prostatic hyperplasia and explores the currently available treatment options for this condition.Translational Andrology and Urology
ConclusionCurrently available IPEMs pertaining to benign prostatic hyperplasia treatment options are written at a level that is too difficult for the average American to understand. Physicians and health networks should take United States Department of Health and Human Services recommendations into consideration when designing IPEMs to optimize accessibility of health information to improve patient compliance and outcomes.